Posters

Intraocular lenses optic power calculation in extremely short eyes

Poster Details

First Author: A.Tsygankov RUSSIA

Co Author(s):    K. Pershin   I. Likh   N. Pashinova              

Abstract Details

Purpose:

The choice of the optimal formula for calculating the IOL optical power in patients with an axial eye length of less than 20 mm

Setting:

Excimer Eye Center, Moscow, Russia

Methods:

A total of 78 patients (118 eyes) were included in the study. Group I included 30 patients (52 eyes) with extremely short eyes (average axial eye length of 19.60 ± 0.42 (18.54-20.0) mm), group II consisted of 48 patients (66 eyes) with a normal axial length (22.75 ± 0.46 (22.0-23.77) mm with implantation of various monofocal IOL models. The average follow-up period was 13 months. IOL optical power was calculated using the SRK / T formula, retrospective comparison - according to the formulas Hoffer-Q, Holladay II, Olsen, Haigis and Barrett Universal II.

Results:

In group I, the maximum average estimation error was determined Haigis formula (0.88±0.35), then for Olsen, Barrett Universal II, SRK/T, Holladay 2 and Hoffer-Q (0.51±0.12, 0,16±0.38, 0.10±0.59, 0.05±0.54 and -0.12±0.42, respectively). For average absolute error it was 0.85±0.31, 0.78±0.25, 0.21±0.10, 0.79±0.23, 0.73±0.24 and 0.19±0.08, respectively. Significant differences were found for Hoffer-Q and Barrett Universal II in comparison with Haigis, Olsen, SRK/T and Holladay II (p˂0.05) in all cases, respectively. In group II, there were no significant differences between the studied formulas (p˂0.05).

Conclusions:

This poster presents an analysis of our own data on the effectiveness of six formulas for calculating the IOL optical power in extremely short (less than 20 mm) eyes in comparison with the normal axial length. The advantage of the Hoffer-Q and Barrett Universal II formulas over Haigis, Holladay 2, Olsen, and SRK / T is shown. To determine the exact indications for using these formulas, further studies are necessary taking into account the anterior chamber depth and a lesser degree of hyperopia.

Financial Disclosure:

None